Neuropace Inc reports results for the quarter ended September 30 - Earnings Summary

NeuroPace

13/11/2024 14:23

* Neuropace Inc  NPCE.OQ  reported a quarterly adjusted loss
of 19
cents​​ per share for the quarter ended September 30, higher
than the same quarter last year, when the company reported EPS
of -28 cents.  The mean expectation of six analysts for the
quarter was for a loss of 27 cents per share. Wall Street
expected results to range from -29 cents to -24 cents per share.
    * Revenue rose 28.2% to $21.06 million from a year ago;
analysts
expected $19.08 million. 
    * Neuropace Inc's reported EPS for the quarter was a loss
of 19
cents​.
    * The company reported a quarterly loss of $5.45 million.
    * Neuropace Inc shares had risen by 2.4% this quarter and
lost 30.7% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"

Wall Street's median 12-month price target for Neuropace Inc is
$16.00 
This summary was machine generated from LSEG data November 13 at
02:23 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.27          -0.19          Beat
 Jun. 30 2024      -0.30          -0.26          Beat
 Mar. 31 2024      -0.32          -0.32          Met
 Dec. 31 2023      -0.31          -0.23          Beat